Back to Agenda
Session 7 Track A, C: Use of Artificial Intelligence in Pharmacovigilance (PV)
Session Chair(s)
Vanessa Zapata
Associate Director, Regional Pharmacovigilance Officer, Merck Canada Inc., Canada
Lucye Galand, DVM, MBA, MSC
Acting Director, BGIVD, Therapeutic Products Directorate, HPFB, Health Canada, Canada
Marcia Bailey, BSN, MHS, RN
Safety Evaluation and Risk Management Scientific Director, GSK, Canada
Artificial Intelligence interest has been continuously increasing in the last few years,especially in the pharmacovigilance area. Some of its applications include Individual Case Safety Report process; Periodic Reporting; Aggregate Data; Signal Detection and Management and Risk Management. This session will give you an overview of where the Canadian regulator and industry are with a focus on specific initiatives that are currently implemented in the industry.
Learning Objective : At the conclusion of this session, participants should be able to:
- Identify the positive impact that AI can have on the PV day-to-day activities
- Understand Canadian Regulator expectations
- Identify areas of opportunity of Ai in PV for the future
Speaker(s)
Benny Ling, MSC
Senior Scientific Evaluator, Marketed Pharmaceuticals Bureau, Health Canada, Canada
Future perspectives in Pharmacovigilance - Artificial Intelligence or Intelligent Automation
Michael Moreyne, MBA
Director, Medical Modernization Canada, Medical & Scientific Affairs, Merck, Canada
Artificial Intelligence is Transforming Medical Value
Oanh Dang, PHARMD
Pharmacotherapy Specialist, Regulatory Science Staff, OSE, CDER, FDA, United States
Speaker
Have an account?